The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I‐MIBG accompanied by ASCT for high‐risk and relapsed neuroblastoma: A pilot study. (12th May 2014)

• Record Type: Journal Article
• Authors: Hamidieh, Amir Ali; Beiki, Davood; Paragomi, Pedram; Fallahi, Babak; Behfar, Maryam; Fard‐Esfahani, Armaghan; Hosseini, Ashraf Sadat; Shamshiri, Ahmadreza; Eftekhari, Mohammad; Ghavamzadeh, Ardeshir
• Is Part Of: Pediatric transplantation. Volume 18:Number 5(2014:Aug.)
• Page Start: 510
• Page End: 517
• Publication Date: 2014-05-12
• Subjects: Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.12271
• Languages: English
• ISSNs: 1397-3142

Abstract

<abstract abstract-type="main" id="petr12271-abs-0001"> <title>Abstract</title> <p>MIBG is an effective component in treatment of neuroblastoma. Furthermore, MIBG scintigraphy is an imaging modality in primary assessments. None of the previous studies have evaluated the role of pretransplant MIBG scintigraphy in decision making for neuroblastoma treatment. We selected therapeutic regimen based on pretransplant <sup>131</sup>I‐MIBG scintigraphy. Twenty high‐risk patients were enrolled. On day −30, patients underwent diagnostic MIBG scintigraphy. Patients were then subdivided into two groups (10 cases in each arm). MIBG‐avid subgroup received MIBG (12 mCi/kg), etoposide (1200 mg/m<sup>2</sup>), carboplatin (1500 mg/m<sup>2</sup>), and melphalan (210 mg/m<sup>2</sup>). Non‐MIBG‐avid subgroup received etoposide (600 mg/m<sup>2</sup>), carboplatin (1200 mg/m<sup>2</sup>), and melphalan (150 mg/m<sup>2</sup>). Patients received CRA after ASCT. Mean age at diagnosis was 42.5 months (range, 17–65) in MIBG‐avid and 38.9 months (range, 18–65) in non‐MIBG‐avid patients. Mean age at diagnosis and transplantation did not reveal significant difference between two subgroups. In MIBG‐avid patients, the three‐yr OS was 66 ± 21%. In MIBG‐non‐avid subgroup, the three‐yr OS was 53 ± 20%. In MIBG‐avid and non‐MIBG‐avid subgroups, the three‐yr EFS were 66 ± 21% and 47 ± 19%, respectively. These findings may suggest an effective role in selecting the therapeutic strategy for pre‐ASCT MIBG scintigraphy in high‐risk neuroblastoma. MIBG‐avid subset may benefit from the combination of therapeutic MIBG and high dose of chemotherapy.</p> </abstract>